Hot issues in the clinical application of protective agents against cardiac toxicity caused by anthracyclines

Long Jiang, Hao Long, Huaqing Wang

    Research output: Contribution to journalReview article

    2 Scopus citations


    Anthracyclines have attracted growing attention because of their significant anti-cancer effect, safe clinical application, and great market demand. However, the cardiac toxicity of anthracycline limits its dosage. Dexrazoxane is the only approved cardioprotective agent that has been widely accepted. Dexrazoxane has also been recommended by many guidelines in China and overseas, such as the American Society of Clinical Oncology 2008 Clinical Practice Guideline. However, controversy surrounds the details of the clinical use of Dexrazoxane. In this paper, we have discussed the possibility that Dexrazoxane influences anti-tumor efficacy. In addition, we have tackled the administration, safety, and other possible cardioprotective effects of Dexrazoxane.

    Original languageEnglish (US)
    Pages (from-to)991-994
    Number of pages4
    JournalChinese Journal of Clinical Oncology
    Issue number16
    StatePublished - Aug 30 2011



    • Anthracyclines
    • Drug toxicity
    • Heart injuries
    • Protective agents

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this